Triveni Bio Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
34
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$115M
- Investors
-
12
Triveni Bio General Information
Description
Developer of drug discovery platform intended to targeted therapies for I&I disorders. The company's uses genetics-informed approach to identify patients who are most likely to respond to their therapies and to improve the precision of treatment and reduce the need for trial and error, to advance the development of new and innovative treatments, helping patients with therapies be more effective and less toxic than current treatments.
Contact Information
Website
www.triveni.bioCorporate Office
- 99 Coolidge Avenue
- Suite 450
- Watertown, MA 02472
- United States
Corporate Office
- 99 Coolidge Avenue
- Suite 450
- Watertown, MA 02472
- United States
Triveni Bio Timeline
Triveni Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series B) | 19-Sep-2024 | $115M | Completed | Pre-Clinical Trials | ||
| 2. Early Stage VC (Series A) | 26-Oct-2023 | Completed | Startup | |||
| 1. Seed Round | $25M | $25M | Completed | Startup |
Triveni Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A-2 | ||||||||
| Series A-1 | ||||||||
| Seed-3 | ||||||||
| Seed-2 | 6,676,725 | $0.000010 | $1.5 | $1.5 | 1x | $1.5 | 2.25% | |
| Seed-1 | 1,000,000 | $0.000010 | $0.4 | $0.4 | 1x | $0.4 | 0.34% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Triveni Bio Comparisons
Industry
Financing
Details
Triveni Bio Competitors (42)
One of Triveni Bio’s 42 competitors is Atomwise, a Venture Capital-Backed company based in San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Atomwise | Venture Capital-Backed | San Francisco, CA | ||||
| Centrose | Venture Capital-Backed | Middleton, WI | ||||
| NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Genesis Therapeutics | Venture Capital-Backed | Burlingame, CA | ||||
| Aurora Biopharma | Angel-Backed | Cambridge, MA |
Triveni Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Triveni Bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Triveni Bio Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Deep Track Capital | Venture Capital | Minority | ||
| Fidelity Management & Research Company | Asset Manager | Minority | ||
| Goldman Sachs Asset Management | Asset Manager | Minority | ||
| Alexandria Venture Investments | Venture Capital | Minority | ||
| Atlas Venture | Venture Capital | Minority |
Triveni Bio Acquisitions (1)
Triveni Bio’s most recent deal was a Merger/Acquisition with Amagma Therapeutics. The deal was made on 26-Nov-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Amagma Therapeutics | 26-Nov-2023 | Merger/Acquisition | Drug Discovery |
Triveni Bio FAQs
-
When was Triveni Bio founded?
Triveni Bio was founded in 2019.
-
Where is Triveni Bio headquartered?
Triveni Bio is headquartered in Watertown, MA.
-
What is the size of Triveni Bio?
Triveni Bio has 34 total employees.
-
What industry is Triveni Bio in?
Triveni Bio’s primary industry is Drug Discovery.
-
Is Triveni Bio a private or public company?
Triveni Bio is a Private company.
-
What is the current valuation of Triveni Bio?
The current valuation of Triveni Bio is .
-
What is Triveni Bio’s current revenue?
The current revenue for Triveni Bio is .
-
How much funding has Triveni Bio raised over time?
Triveni Bio has raised $232M.
-
Who are Triveni Bio’s investors?
Deep Track Capital, Fidelity Management & Research Company, Goldman Sachs Asset Management, Alexandria Venture Investments, and Atlas Venture are 5 of 12 investors who have invested in Triveni Bio.
-
Who are Triveni Bio’s competitors?
Atomwise, Centrose, NexImmune, Genesis Therapeutics, and Aurora Biopharma are some of the 42 competitors of Triveni Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
